トップ > 教育・研究活動 > 教員一覧 > 椿原 美治

椿原 美治

椿原 美治
研究科長/教授
椿原 美治 Yoshiharu Tsubakihara
研究内容・メッセージ

腎臓内科学、透析医学をテーマに、実臨床や臨床研究を行ってきました。特に日本透析医学会の統計調査委員長として、多数のガイドライン作成にも関わってきました。血液透析は通院患者に対して、週3回の体外循環を行う特殊な療法です。透析患者の高齢化、合併症の多様化が急速に進む中で、様々な医療機器や薬剤が開発されており、これに関わる医療者も極めて多岐にわたり、チーム医療が必須です。医療安全の観点からも、チーム全体での合意と実践が必要です。各医療者の研究テーマを基に、エビデンスを創生し、世界に発信しましょう!


学位・資格 医学博士/医師/内科学会認定医/透析医学会・腎臓学会指導医、循環器学会専門医、高血圧学会FJSH
専門領域・分野 透析医学、腎臓内科学
担当科目 透析医療安全管理学、臨床医学概論、特別演習、課題研究(修士論文作成)

略歴

昭和49年和歌山県立医科大卒業、大阪大学医学部大学院入学、昭和53年大学院卒業、大阪府立病院腎臓内科(現大阪府立急性期・総合医療センター腎臓・高血圧内科)医員、平成4年同部長、平成24年大阪大学大学院医学系研究科腎疾患統合医療学寄附講座教授(大阪府立急性期・総合医療センター腎臓・高血圧内科部長兼務)、平成27年4月滋慶医療科学大学院大学教授、平成30年4月から同大学研究科長


社会活動等

日本腎臓学会評議員(1986~2015)、大阪透析研究会幹事(1992~)、第47回大阪透析研究会大会長(1996)、日本透析医学会理事(2002~2014)、大阪CAPD研究会会長(1987~)、日本腎臓財団透析療法従事職員研修運営委員(2001~2013)、大阪府立学校腎検診判定委員会委員長(2004~)、日本透析医学会「慢性腎臓病患者における腎性貧血治療のガイドライン」作成ワーキンググループ委員長(2005~2008)、日本透析医学会統計調査委員会委員長(2006~2014)、大阪腎臓バンク評議員(同学術委員)(2009~)、第59回日本透析医学会学術集会・総会会長(2014)


著書等

「高齢透析患者治療とケアのための透析療法Q&A」(飯田喜俊、椿原美治編)(医歯薬出版 東京 2014年)
「透析医学会 統計調査がわかる逆引き事典」(椿原美治編)(医薬ジャーナル 大阪 2014年)
「かかりつけ医・患者・家族のための見逃しやすい!保存期患者の腎性貧血診療ガイド」(椿原美治)(医薬ジャーナル 大阪 2011年)
「らくらくマスター!透析生活をサポートする患者指導40」(飯田喜俊、椿原美治編)(メディカ出版 大阪 2009年)
「図解CRA症候群―貧血治療がカギとなる 慢性腎臓病と心・血管病の悪循環」(椿原美治編)(医薬ジャーナル 大阪 2009年)
「臨床透析ハンドブック」(飯田喜俊・秋澤忠男、椿原美治監訳)(メディカル・サイエンス・インターナショナル 東京 2009年)
「血液透析はてな?がわかる!なるほどブック―患者・スタッフ100の知りたいに答える」(椿原美治、赤塚東司雄編)(メディカ出版 大阪 2008年)
「蛋白尿、血尿と言われたら!―専門医からの忠告」(園田孝夫、椿原美治編)(医薬ジャーナル 大阪 2002年)
「透析療法のリスクマネージメント」(飯田喜俊・秋澤忠男、椿原美治編)(中外医学社 東京 2002年)
「新標準透析療法」(飯田喜俊、秋澤忠男、椿原美治編)(中外医学社 東京 2001年)
「腎疾患診療のジレンマ―専門医が応えるストラテジー」(飯田喜俊、湯浅繁一、椿原美治編)(金芳堂 京都 1998年)
「これからの透析ガイド―患者・家族・スタッフのために」(椿原美治)(南江堂 東京 1996年)

主な研究業績

2014~2017年欧文


1. Obi Y, Hamano T, (Tsubakihara Y) et al; Committee of Renal Data Registry of the Japanese Society for Dialysis Therapy. Vitamin D Receptor Activator Use and Cause-specific Death among dialysis Patients: a Nationwide Cohort Study using Coarsened Exact Matching. Sci Rep 31(7):41170,2017
2. Kida N, Tsubakihara Y, et al: Usefulness of measurement of heart rate variability by holter ECG in hemodialysis patients. BMC Nephrol 18(1):8,2017
3. Akizawa T, Tsubakihara Y, et al: Effects of Daprodustat, a Novel Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Anemia Management in Japanese Hemodialysis Subjects. Am J Nephrol 45(2):127-135,2017
4. Tsuruya K, Uemura Y, (Tsubakihara Y) et al: Association between responsiveness to methoxy polyethylene glycol-epoetin beta and renal survival in patients with non-dialysis-dependent chronic kidney disease: A pooled analysis of individual patient-level data from clinical trials. Nephrology (Carlton) 22(10):769-775,2017
5. Yazawa M, Kido R, (Tsubakihara Y) et al: Early Mortality Was Highly and Strongly Associated with Functional Status in Incident Japanese Hemodialysis Patients: A Cohort Study of the Large National Dialysis Registry. PLoS One 11(12):e0168811,2016
6. Watanabe Y, Akizawa T, (Tsubakihara Y) et al: Co-JET Study Group. Effect of Predialysis Recombinant Human Erythropoietin on Early Survival After Hemodialysis Initiation in Patients With Chronic Kidney Disease: Co-JET Study. Ther Apher Dial 20(6):598-607,2016
7. Yazawa M, Kido R, (Tsubakihara Y) et al: Early Mortality Was Highly and Strongly Associated with Functional Status in Incident Japanese Hemodialysis Patients: A Cohort Study of the Large National Dialysis Registry. PLoS One. 7;11(6):e0156951,2016
8. Sakao Y, Ojima T, (Tsubakihara Y) et al: Serum Creatinine Modifies Associations between Body Mass Index and Mortality and Morbidity in Prevalent Hemodialysis Patients. PLoS One 11(3):e0150003,2016
9. Akizawa T, Tsubakihara Y, et al: JET-STREAM Study Group. A prospective observational study of early intervention with erythropoietin therapy and renal survival in non-dialysis chronic kidney disease patients with anemia:JET-STREAM Study. Clin Exp Nephrol 20(6):885-895,2016
10. Sumida K, Yamagata K, (Tsubakihara Y) et al: Different impact of hemodialysis vintage on cause-specific mortality in long-term hemodialysis patients. Nephrol Dial Transplant 31(2):298-305,2016
11. Hoshino J, Yamagata K, (Tsubakihara Y) et al: Significance of the decreased risk of dialysis-related amyloidosis now proven by results from Japanese nationwide surveys in 1998 and 2010. Nephrol Dial Transplant 31(4):595-602,2016
12. Imai E, Maruyama S, (Tsubakihara Y) et al: Rationale and study design of a randomized controlled trial to assess the effects of maintaining hemoglobin levels using darbepoetin alfa on prevention of development of end-stage kidney disease in non-diabetic CKD patients (PREDICT Trial). Clin Exp Nephrol 20(1):71-76,2016
13. Shoji T, Marubayashi S, (Tsubakihara Y) et al: Committee of Renal Data Registry; Japanese Society for Dialysis Therapy. Use of vitamin D receptor activator, incident cardiovascular disease and death in a cohort of hemodialysis patients. Ther Apher Dial 19(3):235-244,2015
14. Kaneko T, Tsubakihara Y, et al: Histochemical and immunoelectron microscopic analysis of ganglioside GM3 in human kidney. Clin Exp Nephrol 19(3):403-410,2015
15. Teranishi J, Yamamoto R, (Tsubakihara Y) et al: ACE insertion/deletion polymorphism (rs1799752) modifies the renoprotective effect of renin-angiotensin system blockade in patients with IgA nephropathy. J Renin Angiotensin Aldosterone Syst 16(3):633-641,2015
16. Maruyama Y, Yokoyama K, (Tsubakihara Y) et al: The Different Association between Serum Ferritin and Mortality in Hemodialysis and Peritoneal Dialysis Patients Using Japanese Nationwide Dialysis Registry. PLoS One 10(11):e0143430,2015
17. Ogata S, Nishi S, (Tsubakihara Y) et al: Institutional factors influencing regional differences in the 1-year survival of dialysis patients. Hemodial Int 19 (Suppl 3):S5-10,2015
18. Komaba H, Taniguchi M, (Tsubakihara Y) et al: The Authors Reply. Kidney Int 88(3):638-639,2015
19. Hasegawa T, Nakai S, (Tsubakihara Y) et al: Peritoneal Dialysis Registry With 2012 Survey Report. Ther Apher Dial 19(6):529-39,2015
20. Kusunoki Y, Matsui I, (Tsubakihara Y) et al: Excess 25-hydroxyvitamin D3 exacerbates tubulointerstitial injury in mice by modulating macrophage phenotype.Kidney Int 88(5):1013-1029,2015
21. Hamano T, Fujii N, (Tsubakihara Y) et al: Thresholds of iron markers for iron deficiency erythropoiesis-finding of the Japanese nationwide dialysis registry. Kidney Int Suppl (2011) 5(1):23-32,2015
22. Hanafusa N, Nakai S, (Tsubakihara Y) et al: Japanese society for dialysis therapy renal data registry-a window through which we can view the details of Japanese dialysis population. Kidney Int Suppl (2011) 5(1):15-22,2015
23. Sakaguchi Y, Iwatani H, (Tsubakihara Y) et al: Magnesium modifies the association between serum phosphate and the risk of progression to end-stage kidney disease in patients with non-diabetic chronic kidney disease. Kidney Int 88(4):833-842,2015
24. Yamamoto T, Shoji S, (Tsubakihara Y) et al: Predialysis and Postdialysis pH and Bicarbonate and Risk of All-Cause and Cardiovascular Mortality in Long-term Hemodialysis Patients. Am J Kidney Dis 66(3):469-478,2015
25. Tsubakihara Y, Akizawa T, et al: High Hemoglobin Levels Maintained by an Erythropoiesis-Stimulating Agent Improve Renal Survival in Patients with Severe Renal Impairment. Ther Apher Dial 19(5):457-465,2015
26. Watanabe Y, Yamagata K, (Tsubakihara Y) et al: “Hemodialysis Initiation for Maintenance Hemodialysis” Guideline Working Group, Japanese Society for Dialysis Therapy. Japanese society for dialysis therapy clinical guideline for "hemodialysis initiation for maintenance hemodialysis". Ther Apher Dial (Suppl 1):93-107,2015
27. Komaba H, Taniguchi M, (Tsubakihara Y) et al: Parathyroidectomy and survival among Japanese hemodialysis patients with secondary hyperparathyroidism. Kidney Int 88(2):350-359,2015
28. Hasegawa T, Nakai S, (Tsubakihara Y) et al: Dialysis fluid endotoxin level and mortality in maintenance hemodialysis: a nationwide cohort study. Am J Kidney Dis 65(6):899-904,2015
29. Sakaguchi Y, Fujii N, (Tsubakihara Y) et al: Committee of Renal Data Registry of the Japanese Society for Dialysis Therapy. Magnesium modifies the cardiovascular mortality risk associated with hyperphosphatemia in patients undergoing hemodialysis: a cohort study. PLoS One 9(12):e116273,2014
30. Nakai S, Hanafusa N, (Tsubakihara Y) et al: An overview of regular dialysis treatment in Japan (as of 31 December 2012). Ther Apher Dial 18(6):535-602,2014
31. Tagawa M, Hamano T, (Tsubakihara Y) et al: Mineral Metabolism Markers Are Associated with Myocardial Infarction and Hemorrhagic Stroke but Not Ischemic Stroke in Hemodialysis Patients: A Longitudinal Study. PLoS One 9(12):e114678,2014
32. Sakaguchi Y, Fujii N, (Tsubakihara Y) et al: Committee of Renal Data Registry of the Japanese Society for Dialysis Therapy. The authors reply. Kidney Int 86(4):856-857,2014
33. Takahara Y, Matsuda Y, (Tsubakihara Y) et al; Lanthanum Carbonate Study Group: Efficacy and safety of lanthanum carbonate in pre-dialysis CKD patients with hyperphosphatemia: a randomized trial. Clin Nephrol 82(3):181-190,2014
34. Sakaguchi Y, Fujii N, (Tsubakihara Y) et al; Committee of Renal Data Registry of the Japanese Society for Dialysis Therapy. The authors reply. Kidney Int 86(1):212-213,2014/td>
35. Hoshino J, Yamagata K, (Tsubakihara Y) et al: Carpal tunnel surgery as proxy for dialysis-related amyloidosis: results from the Japanese society for dialysis therapy. Am J Nephrol 39(5):449-458,2014
36. Shinzawa M, Yamamoto R, (Tsubakihara Y) et al: Comparison of methylprednisolone plus prednisolone with prednisolone alone as initial treatment in adult-onset minimal change disease: a retrospective cohort study. Clin J Am Soc Nephrol 9(6):1040-1048,2014
37. Wakasugi M, Kazama JJ, (Tsubakihara Y) et al: Regional variation in hip fracture incidence among Japanese hemodialysis patients. Ther Apher Dial 18(2):162-166,2014
38. Akizawa T, Saito A, (Tsubakihara Y) et al (Co-JET Study Group): Impacts of recombinant human erythropoietin treatment during predialysis periods on the progression of chronic kidney disease in a large-scale cohort study (Co-JET study). Ther Apher Dial 18(2):140-148,2014
39. Shimamoto K, Ando K, (Tsubakihara Y) et al (Japanese Society of Hypertension Committee for Guidelines for the Management of Hypertension. The Japanese Society of Hypertension): Guidelines for the Management of Hypertension (JSH 2014). Hypertens Res 37(4):253-390,2014
40. Shimomura A, Matsui I, (Tsubakihara Y) et al: Dietary L-lysine prevents arterial calcification in adenine-induced uremic rats. J Am Soc Nephrol 25(9):1954-1965,2014
41. Maruyama Y, Taniguchi M, (Tsubakihara Y) et al: A higher serum alkaline phosphatase is associated with the incidence of hip fracture and mortality among patients receiving hemodialysis in Japan. Nephrol Dial Transplant 29(8):1532-1538,2014
42. Akizawa T, Saito A, (Tsubakihara Y) et al: JET Study Group. Low hemoglobin levels and hypo-responsiveness to erythropoiesis-stimulating agent associated with poor survival in incident Japanese hemodialysis patients. Ther Apher Dial 18(5):404-413,2014
43. Sakaguchi Y, Tsubakihara Y, et al: Does hypomagnesemia predict faster progression of nondiabetic chronic kidney disease? Am J Med 127(2):e13,2014
44. Obi Y, Hamano T, (Tsubakihara Y) et al: Vitamin D deficiency predicts decline in kidney allograft function: a prospective cohort study. J Clin Endocrinol Metab 99(2):527-535,2014
45. Inoue K, Hamano T, (Tsubakihara Y) et al: Multidetector-row computed tomography is useful to evaluate the therapeutic effects of bisphosphonates in glucocorticoid-induced osteoporosis. J Bone Miner Metab 32(3):271-280,2014